Last reviewed 2026-04-20 · How we verify

Athinazone (ETAQUALONE)

Phase 2 active Small molecule

Athinazone (generic name: ETAQUALONE) is a etaqualone drug. It is currently in Phase 2 development.

Athinazone is thought to work by interacting with the central nervous system, but its exact mechanism of action is not well understood.

Athinazone (ETAQUALONE) is a small molecule drug of the etaqualone class, but its target and exact mechanism of action are unknown. It is not FDA-approved for any indications. The commercial status of Athinazone is unclear, and it may be patented or off-patent. Key safety considerations are not well-documented. Further research is needed to understand its pharmacological properties and potential therapeutic applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETAQUALONE
Drug class	etaqualone
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your brain is a city with many different neighborhoods. Athinazone is like a special key that unlocks certain doors in the city, but we don't know which doors or how it affects the city's traffic. This means we don't know exactly how it helps or harms people who take it.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Athinazone CI brief — competitive landscape report
Athinazone updates RSS · CI watch RSS

Frequently asked questions about Athinazone

What is Athinazone?

Athinazone (ETAQUALONE) is a etaqualone drug.

How does Athinazone work?

Athinazone is thought to work by interacting with the central nervous system, but its exact mechanism of action is not well understood.

What is the generic name of Athinazone?

ETAQUALONE is the generic (nonproprietary) name of Athinazone.

What drug class is Athinazone in?

Athinazone belongs to the etaqualone class. See all etaqualone drugs at /class/etaqualone.

What development phase is Athinazone in?

Athinazone is in Phase 2.

Drug class: All etaqualone drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing